Comparative Inhibitory Effects of Natural Biflavones from Ginkgo against Human CYP1B1 in Recombinant Enzymes and MCF-7 Cells

Abstract

Human cytochrome P450 1B1 (CYP1B1) is an extrahepatic enzyme overexpressed in many tumors and associated with angiogenesis. Ginkgetin, isoginkgetin, sciadopitysin, and amentoflavone, the primary biflavones found in Ginkgo biloba, have excellent anti-inflammatory and anti-tumor effects. However, the effect of biflavones on CYP1B1 activities remains unknown. In this study, 7-ethoxyresorufin O-deethylation (EROD) was used to characterize the activities of CYP1 families. The impacts of four ginkgo biflavones on CYP1B1 activity and the cellular protein expression of CYP1B1 were systematically investigated. The results showed that amentoflavone with six hydroxyl substituents exhibited the most potent selective inhibitory effect on CYP1B1 activity with IC₅₀ of 0.054 µM in four biflavones. Sciadopitysin, with three hydroxyl and three methoxy substituents, had the weakest inhibitory activity against CYP1B1. Ginkgetin and isoginkgetin, both with four hydroxyl and two methoxy substituents, showed similar inhibitory intensity towards CYP1B1 with IC₅₀ values of 0.289 and 0.211 µM, respectively. Kinetic analysis showed that ginkgetin and amentoflavone inhibited CYP1B1 in a non-competitive mode, whereas sciadopitysin and isoginkgetin induced competitive or mixed types of inhibition. Notably, four ginkgo biflavones were also confirmed to suppress the protein expressions of CYP1B1 and AhR in MCF-7. Furthermore, molecular docking studies indicated more hydrogen bonds formed between amentoflavone and CYP1B1, which might explain the strongest inhibitory action towards CYP1B1. In summary, these findings suggested that biflavones remarkably inhibited both the activity and protein expression of CYP1B1 and the inhibitory activities enhanced with the increasing hydroxyl substitution, providing new insights into the anti-tumor potentials of biflavones.

Key words

CYP1B1 - Ginkgo biloba - biflavones - inhibition - AhR - structure-inhibition relationship

Publication History

Received: 12 April 2022

Accepted after revision: 25 August 2022

Accepted Manuscript online:
05 September 2022

Article published online:
05 December 2022

• References

• 1 Li Y, Cheng Z, Wang K, Zhu X, Ali Y, Shu W, Bao X, Zhu L, Fan X, Murray M, Zhou F. Procyanidin B2 and rutin in ginkgo biloba extracts protect human retinal pigment epithelial (RPE) cells from oxidative stress by modulating Nrf2 and Erk1/2 signalling. Exp Eye Res 2021; 207: 108586
• 2 Tian J, Liu Y, Chen K. Ginkgo biloba extract in vascular protection: Molecular mechanisms and clinical applications. Curr Vasc Pharmacol 2017; 15: 532-548
• 3 Song W, Zhao J, Yan XS, Fang X, Huo DS, Wang H, Jia JX, Yang ZJ. Mechanisms associated with protective effects of ginkgo biloba leaf extracton in rat cerebral ischemia reperfusion injury. J Toxicol Environ Health A 2019; 82: 1045-1051
• 4 Singh SK, Srivastav S, Castellani RJ, Plascencia-Villa G, Perry G. Neuroprotective and antioxidant effect of ginkgo biloba extract against AD and other neurological disorders. Neurotherapeutics 2019; 16: 666-674
• 5 Zheng X, Gao Q, Liang S, Zhu G, Wang D, Feng Y. Cardioprotective properties of ginkgo biloba extract 80 via the activation of AKT/GSK3β/β-catenin signaling pathway. Front Mol Biosci 2021; 8: 771208
• 6 Kang JM, Lin S. Ginkgo biloba and its potential role in glaucoma. Curr Opin Ophthalmol 2018; 29: 116-120
• 7 Luo K, Zhang J, Lei J, Li L, Guo L. Determination of biflavonoids in ginkgo by HPLC. Chemical Reagents 2020; 42: 58-61
• 8 Waterman MJ, Nugraha AS, Hendra R, Ball GE, Robinson SA, Keller PA. Antarctic moss biflavonoids show high antioxidant and ultraviolet-screening activity. J Nat Prod 2017; 80: 2224-2231
• 9 Tao Z, Jin W, Ao M, Zhai S, Xu H, Yu L. Evaluation of the anti-inflammatory properties of the active constituents in ginkgo biloba for the treatment of pulmonary diseases. Food Funct 2019; 10: 2209-2220
• 10 Adnan M, Rasul A, Hussain G, Shah MA, Zahoor MK, Anwar H, Sarfraz I, Riaz A, Manzoor M, Adem Ş, Selamoglu Z. Ginkgetin: A natural biflavone with versatile pharmacological activities. Food Chem Toxicol 2020; 145: 111642
• 11 Zhang J, Yang S, Chen F, Li H, Chen B. Ginkgetin aglycone ameliorates LPS-induced acute kidney injury by activating SIRT1 via inhibiting the NF-κB signaling pathway. Cell Biosci 2017; 7: 44
• 12 Cao J, Tong C, Liu Y, Wang J, Ni X, Xiong MM. Ginkgetin inhibits growth of breast carcinoma via regulating MAPKs pathway. Biomed Pharmacother 2017; 96: 450-458
• 13 Park Y, Woo SH, Seo SK, Kim H, Noh WC, Lee JK, Kwon BM, Min KN, Choe TB, Park IC. Ginkgetin induces cell death in breast cancer cells via downregulation of the estrogen receptor. Oncol Lett 2017; 14: 5027-5033
• 14 Ye ZN, Yu MY, Kong LM, Wang WH, Yang YF, Liu JQ, Qiu MH, Li Y. Biflavone ginkgetin, a novel Wnt inhibitor, suppresses the growth of medulloblastoma. Nat Prod Bioprospect 2015; 5: 91-97
• 15 Song YQ, He RJ, Pu D, Guan XQ, Shi JH, Li YG, Hou J, Jia SN, Qin WW, Fang SQ, Ge GB. Discovery and characterization of the biflavones from ginkgo biloba as highly specific and potent inhibitors against human carboxylesterase 2. Front Pharmacol 2021; 12: 655659
• 16 Qiu S, Zhou Y, Kim JT, Bao C, Lee HJ, Chen J. Amentoflavone inhibits tumor necrosis factor-α-induced migration and invasion through AKT/mTOR/S6k1/hedgehog signaling in human breast cancer. Food Funct 2021; 12: 10196-10209
• 17 Tsuchiya Y, Nakajima M, Yokoi T. Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett 2005; 227: 115-124
• 18 Gajjar K, Martin-Hirsch PL, Martin FL. CYP1B1 and hormone-induced cancer. Cancer Lett 2012; 324: 13-30
• 19 Hevir N, Sinkovec J, Rižner TL. Disturbed expression of phase I and phase II estrogen-metabolizing enzymes in endometrial cancer: lower levels of CYP1B1 and increased expression of S-COMT. Mol Cell Endocrinol 2011; 331: 158-167
• 20 Sasaki M, Kaneuchi M, Fujimoto S, Tanaka Y, Dahiya R. CYP1B1 gene in endometrial cancer. Mol Cell Endocrinol 2003; 202: 171-176
• 21 Martinez VG, OʼConnor R, Liang Y, Clynes M. CYP1B1 expression is induced by docetaxel: Effect on cell viability and drug resistance. Br J Cancer 2008; 98: 564-570
• 22 Sissung TM, Price DK, Sparreboom A, Figg WD. Pharmacogenetics and regulation of human cytochrome P450 1B1: Implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention. Mol Cancer Res 2006; 4: 135-150
• 23 Nishida CR, Everett S, Ortiz de Montellano PR. Specificity determinants of CYP1B1 estradiol hydroxylation. Mol Pharmacol 2013; 84: 451-458
• 24 Bolton JL, Thatcher GR. Potential mechanisms of estrogen quinone carcinogenesis. Chem Res Toxicol 2008; 21: 93-101
• 25 Fotsis T, Zhang Y, Pepper MS, Adlercreutz H, Montesano R, Nawroth PP, Schweigerer L. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 1994; 368: 237-239
• 26 Lin H, Hu B, He X, Mao J, Wang Y, Wang J, Zhang T, Zheng J, Peng Y, Zhang F. Overcoming Taxol-resistance in A549 cells: A comprehensive strategy of targeting P-gp transporter, AKT/ERK pathways, and cytochrome P450 enzyme CYP1B1 by 4-hydroxyemodin. Biochem Pharmacol 2020; 171: 113733
• 27 Yang X, Solomon S, Fraser LR, Trombino AF, Liu D, Sonenshein GE, Hestermann EV, Sherr DH. Constitutive regulation of CYP1B1 by the Aryl hydrocarbon Receptor (AhR) in pre-malignant and malignant mammary tissue. J Cell Biochem 2008; 104: 402-417
• 28 Yin J, Sheng B, Han B, Pu A, Yang K, Li P, Wang Q, Xiao W, Yang H. The AhR is involved in the regulation of LoVo cell proliferation through cell cycle-associated proteins. Cell Biol Int 2016; 40: 560-568
• 29 Gutiérrez-Vázquez C, Quintana FJ. Regulation of the immune response by the Aryl hydrocarbon Receptor. Immunity 2018; 48: 19-33
• 30 Lv Q, Shi C, Qiao S, Cao N, Guan C, Dai Y, Wei Z. Alpinetin exerts anti-colitis efficacy by activating AhR, regulating miR-302/DNMT-1/CREB signals, and therefore promoting Treg differentiation. Cell Death Dis 2018; 9: 890
• 31 Malaplate-Armand C, Ferrari L, Masson C, Siest G, Batt AM. Astroglial CYP1B1 up-regulation in inflammatory/oxidative toxic conditions: IL-1beta effect and protection by N-acetylcysteine. Toxicol Lett 2003; 138: 243-251
• 32 Umannová L, Machala M, Topinka J, Nováková Z, Milcová A, Kozubík A, Vondrácek J. Tumor necrosis factor-alpha potentiates genotoxic effects of benzo[a]pyrene in rat liver epithelial cells through upregulation of cytochrome P450 1B1 expression. Mutat Res 2008; 640: 162-169
• 33 Jenkins CM, Cedars A, Gross RW. Eicosanoid signalling pathways in the heart. Cardiovasc Res 2009; 82: 240-249
• 34 Maayah ZH, Althurwi HN, Abdelhamid G, Lesyk G, Jurasz P, El-Kadi AO. CYP1B1 inhibition attenuates doxorubicin-induced cardiotoxicity through a mid-chain HETEs-dependent mechanism. Pharmacol Res 2016; 105: 28-43
• 35 Zhu Z, Mu Y, Qi C, Wang J, Xi G, Guo J, Mi R, Zhao F. CYP1B1 enhances the resistance of epithelial ovarian cancer cells to paclitaxel in vivo and in vitro. Int J Mol Med 2015; 35: 340-348
• 36 Li F, Zhu W, Gonzalez FJ. Potential role of CYP1B1 in the development and treatment of metabolic diseases. Pharmacol Ther 2017; 178: 18-30
• 37 Takemura H, Itoh T, Yamamoto K, Sakakibara H, Shimoi K. Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem 2010; 18: 6310-6315
• 38 Chun YJ, Kim S. Discovery of cytochrome P450 1B1 inhibitors as new promising anti-cancer agents. Med Res Rev 2003; 23: 657-668
• 39 Cui J, Li S. Inhibitors and prodrugs targeting CYP1: A novel approach in cancer prevention and therapy. Curr Med Chem 2014; 21: 519-552
• 40 Dong J, Huang G, Cui Q, Meng Q, Li S, Cui J. Discovery of heterocycle-containing α-naphthoflavone derivatives as water-soluble, highly potent and selective CYP1B1 inhibitors. Eur J Med Chem 2021; 209: 112895
• 41 Cui J, Meng Q, Zhang X, Cui Q, Zhou W, Li S. Design and synthesis of new α-naphthoflavones as cytochrome P450 (CYP) 1B1 inhibitors to overcome docetaxel-resistance associated with CYP1B1 overexpression. J Med Chem 2015; 58: 3534-3547
• 42 DʼUva G, Baci D, Albini A, Noonan DM. Cancer chemoprevention revisited: Cytochrome P450 family 1B1 as a target in the tumor and the microenvironment. Cancer Treat Rev 2018; 63: 1-18
• 43 Androutsopoulos VP, Papakyriakou A, Vourloumis D, Spandidos DA. Comparative CYP1A1 and CYP1B1 substrate and inhibitor profile of dietary flavonoids. Bioorg Med Chem 2011; 19: 2842-2849
• 44 Doostdar H, Burke MD, Mayer RT. Bioflavonoids: selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1. Toxicology 2000; 144: 31-38
• 45 Shimada T, Kim D, Murayama N, Tanaka K, Takenaka S, Nagy LD, Folkman LM, Foroozesh MK, Komori M, Yamazaki H, Guengerich FP. Binding of diverse environmental chemicals with human cytochromes P450 2A13, 2A6, and 1B1 and enzyme inhibition. Chem Res Toxicol 2013; 26: 517-528
• 46 Shimada T, Tanaka K, Takenaka S, Murayama N, Martin MV, Foroozesh MK, Yamazaki H, Guengerich FP, Komori M. Structure-function relationships of inhibition of human cytochromes P450 1A1, 1A2, 1B1, 2C9, and 3A4 by 33 flavonoid derivatives. Chem Res Toxicol 2010; 23: 1921-1935
• 47 Don MJ, Lewis DF, Wang SY, Tsai MW, Ueng YF. Effect of structural modification on the inhibitory selectivity of rutaecarpine derivatives on human CYP1A1, CYP1A2, and CYP1B1. Bioorg Med Chem Lett 2003; 13: 2535-2538
• 48 Chaudhary A, Willett KL. Inhibition of human cytochrome CYP 1 enzymes by flavonoids of St. Johnʼs wort. Toxicology 2006; 217: 194-205
• 49 Meng X, Sun H, Yang L, Yin R, Qi L. A hydroxylated flavonol, fisetin inhibits the formation of a carcinogenic estrogen metabolite. Steroids 2017; 119: 53-56
• 50 Wang Y, He X, Li C, Ma Y, Xue W, Hu B, Wang J, Zhang T, Zhang F. Carvedilol serves as a novel CYP1B1 inhibitor, a systematic drug repurposing approach through structure-based virtual screening and experimental verification. Eur J Med Chem 2020; 193: 112235
• 51 Li JN, Cao YF, He RR, Ge GB, Guo B, Wu JJ. Evidence for Shikonin acting as an active inhibitor of human carboxylesterases 2: Implications for herb-drug combination. Phytother Res 2018; 32: 1311-1319